INS and cancer: This suggests that while the underlying anti-cancer mechanisms of the two agents are different (dapagliflozin reduces systemic glucose and insulin concentrations, which may slow tumor growth by metabolic modulation, and paclitaxel causes microtubule instability), dapagliflozin may sensitize cells to vulnerability to paclitaxel by altering tumor glucose metabolism.